Sensei Biotherapeutics reports Q1 EPS (27c) vs (32c) last year

Written by Emily J. Thompson, Senior Investment Analyst

SNSE-4.17%

Updated: May 06 2025

0mins

Breakthrough in Clinical Activity: Sensei reported significant clinical activity in patients with PD-(L)1-resistant cancers, showing response rates nearly three times higher than expected, with some patients nearing a year on study.
Focus on Phase 2 Strategy: With dose expansion enrollment complete, Sensei is concentrating on finalizing a Phase 2 strategy for solnerstotug, guided by the upcoming full dataset presentation later this year.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like SNSE with instant alerts to capture every critical market movement.

SNSE

$9.66+Infinity%1D

Analyst Views on SNSE

About SNSE

Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.